Cargando…

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster

Detalles Bibliográficos
Autores principales:	Salvagno, G.L., Henry, B.M., Lippi, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259019/ https://www.ncbi.nlm.nih.gov/pubmed/35809859 http://dx.doi.org/10.1016/j.idnow.2022.06.007

Ejemplares similares

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

The Comparability of Anti-SARS-CoV-2 IgG Levels Measured with Different Immunoassays Varies over Time after Primary BNT162b2 Vaccination and Homologous Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
por: Lippi, Giuseppe, et al.
Publicado: (2021)

Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
por: Danese, Elisa, et al.
Publicado: (2021)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
por: Rechavi, Yoav, et al.
Publicado: (2021)

Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273
por: Ailsworth, Samuel M., et al.
Publicado: (2023)

Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection
por: Pratò, Simone, et al.
Publicado: (2021)

Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers
por: Ramos, Angélica, et al.
Publicado: (2022)

Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster
por: Chantasrisawad, Napaporn, et al.
Publicado: (2022)

Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
por: Benucci, Maurizio, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
por: Glatman-Freedman, Aharona, et al.
Publicado: (2022)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2022)

Persistence of IgG response to SARS-CoV-2
por: Duysburgh, Els, et al.
Publicado: (2021)

Not all SARS-CoV-2 IgG and neutralizing antibody assays are created equal
por: Lippi, Giuseppe, et al.
Publicado: (2022)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
por: Perkmann, Thomas, et al.
Publicado: (2021)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
por: Fonseca, Marcela Helena Gambim, et al.
Publicado: (2022)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
por: Herman-Edelstein, Michal, et al.
Publicado: (2022)

IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity
por: Bates, John T., et al.
Publicado: (2022)

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
por: Lo Sasso, Bruna, et al.
Publicado: (2022)

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection
por: Keshavarz, Behnam, et al.
Publicado: (2022)

418. Comparison of the Abbott SARS-CoV-2 IgG and DiaSorin LIASON SARS-CoV-2 S1/S2 IgG Antibody Assays
por: Schaack, Grace A, et al.
Publicado: (2020)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
por: Urbanowicz, Richard A., et al.
Publicado: (2021)

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
por: Giambra, Vincenzo, et al.
Publicado: (2022)

Evaluation of the Effectiveness of BNT162b2 Primary Vaccination and Booster Dose to SARS-CoV-2 in Eliciting Stable Mucosal Immunity
por: Lambiase, Alessandro, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2023)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
por: Padhiar, Nigam H., et al.
Publicado: (2022)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
por: Van Coillie, Julie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ooas6ugn9ep4h057p41c8htqju